Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
13.70
+0.46 (3.47%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Zymeworks Revenue
Zymeworks had revenue of $19.24M in the quarter ending June 30, 2024, with 174.82% growth. This brings the company's revenue in the last twelve months to $62.71M, down -85.99% year-over-year. In the year 2023, Zymeworks had annual revenue of $76.01M, down -81.57%.
Revenue (ttm)
$62.71M
Revenue Growth
-85.99%
P/S Ratio
16.06
Revenue / Employee
$225,558
Employees
278
Market Cap
973.35M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetIQ | 1.13B |
Phibro Animal Health | 1.02B |
Bioventus | 536.89M |
Castle Biosciences | 287.59M |
CeriBell | 54.46M |
Liquidia | 14.84M |
ZYME News
- 19 hours ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewsWire
- 8 days ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers - GlobeNewsWire
- 19 days ago - Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024 - GlobeNewsWire
- 4 weeks ago - Zymeworks Approaching A Moment Of Truth With Zanidatamab - Seeking Alpha
- 5 weeks ago - Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewsWire
- 2 months ago - Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) - GlobeNewsWire
- 3 months ago - Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript - Seeking Alpha